Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

iate the TIME-1 trial at the end of 2007 or early 2008.

"Kosan's successful completion of both the Special Protocol Assessment process with the FDA and Scientific Advice from the EMEA for our TIME-1 trial provides us with a clear roadmap to registration in major countries around the world for this potentially important new treatment for patients with multiple myeloma," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "We believe that Kosan's TIME program is the most advanced Hsp90 inhibitor clinical program in the industry, underscoring Kosan's leadership in this promising new class of anticancer therapies. We appreciate the widespread support we have received from the US and international myeloma clinician and patient communities."

About TIME

The TIME clinical program utilizes Kosan's improved, proprietary injectable suspension formulation of tanespimycin. The injectable suspension formulation is designed to provide important benefits, including improved patient safety, due to the elimination of Cremophor(R) and the associated need for steroid premedication to prevent hypersensitivity reactions. Tanespimycin injectable suspension also has a potentially enhanced intellectual property position and permits easier drug preparation and administration compared to the prior formulation.

The TIME-1 trial will be an open-label, randomized, multi-center trial conducted in the US and in Europe that is designed to enroll over 450 patients with relapse of multiple myeloma following a single prior course of treatment (first-relapse). The trial is designed to compare two groups: patients treated with bortezomib plus tanespimycin and patients treated with bortezomib alone. Tanespimycin will be administered at a dose of 340 mg/m2 and all patients will receive standard doses of bortezomib (1.3 mg/m2). TIME-1 is designed with a primary endpoint of progression-free survival. TIME-1 is designed to include an interim analys
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 Cardiologists at Beaumont ... the Midwest,s first commercial implant of a device recently ... with non-valvular atrial fibrillation. The Watchman Left Atrial Appendage ... blood-thinning warfarin medication to reduce the risk of stroke. ... rhythm disorder affecting more than 5 million Americans. Twenty ...
(Date:3/26/2015)... 2015 Over-the-counter healthcare costs can be ... a new survey of store brand over-the-counter products ... cold to diabetes, can offer significant savings for ... the Private Label Manufacturers Association, assembled a market ... those essential for treatment of pre-diabetes and diabetes. ...
(Date:3/26/2015)... March 26, 2015 Zimmer Holdings, Inc. (NYSE ... ® Advanced Bearing Technology with Vitamin E by ... published earlier this month reported that, at 96 million ... Advanced Bearing Technology featuring Vitamin E grafted highly crosslinked ... wear rate reduction of 95 percent, with no cracking, ...
Breaking Medicine Technology:Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3Consumers can keep over-the-counter medicine affordable by using store brands 2Zimmer Announces New Testing Milestone For Vitamin E Advanced Bearing Technology 2Zimmer Announces New Testing Milestone For Vitamin E Advanced Bearing Technology 3
... SAN DIEGO, Aug. 4, 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: ... for the quarter ended June 30, 2011. (Logo: ... for the second quarter of 2011 of $24.2 million, or ... as compared to a net loss for the second ...
... Dehaier Medical Systems Ltd. (Nasdaq: ... in the development, assembly, marketing and sale of medical ... that it will release financial results for the second ... Monday, August 15, 2011 before the start of trading ...
Cached Medicine Technology:Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 2Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 3Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 4Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 5Dehaier Medical to Report Second Quarter 2011 Financial Results on August 15 2
(Date:3/27/2015)... March 27, 2015 DrugDev announced company ... Easy was named to the 2015 Philadelphia Business Journal ... list spotlights 40 dynamic, up-and-coming leaders less than 40 ... involvement. Winners are honored at an awards program in ... Philadelphia Business Journal. , Lyn Kremer, Publisher of the ...
(Date:3/27/2015)... UK (PRWEB) March 27, 2015 GenSight, ... it has appointed Sean Fitzgerald, a former technology and ... Operating Officer and Interim Chief Financial Officer. , Mr ... education technology innovator, EverFi, backed by Amazon founder and ... founder Evan Williams. Prior to EverFi, he was a ...
(Date:3/27/2015)... 2015 Operatic contenders and their avid ... April 17th. The universally acclaimed baritone Sherrill Milnes will ... Opera Idol at The Merion in Evanston. The event ... drawn aspiring opera singers from around the country. “This ... the finest young talent in the country,” said Margaret ...
(Date:3/27/2015)... Since September 2014, the country singer has been ... having been in retirement for a period of 13 years. ... return to touring, and concert events have been booking quickly ... sell out for the two shows recently scheduled for May ... the inventory of discounted Garth Brooks tickets for sale. , ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 “ VXi ... of its monthly Tech Report, which features the latest ... a technology expert and special reporter for NewsWatch, conducted ... an advanced noise-cancelling headset, eliminating 90% of ambient noise. ... while texts and emails are important to any professional, ...
Breaking Medicine News(10 mins):Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:GenSight Appoints Former Technology Executive as Chief Operating Officer 2Health News:Opera Idol Competition At The Merion In Evanston 2Health News:Garth Brooks Tickets for Omaha: BuyCheapTicketsToEvents.com Draws Customers by Discounting Prices on 2015 Tickets for Garth Brooks’ Tour Stops at CenturyLink Center 2Health News:A Device to Tune out Background Noise was Recently Featured on NewsWatch Television 2
... , TORONTO, July 17 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals ... that its Board of Directors has authorized the Corporation ... pursuant to which the Corporation will offer to purchase ... common shares ("Shares") at a price of Cdn$0.20 (approximately ...
... ... healthcare associations to address high workforce shortage of lab professionals , ... Washington DC (PRWEB) July 17, 2009 ... based in Chicago, today announced it is joining the National Healthcare Career Network (NHCN). ...
... ... , ... July 17, 2009 -- Virtual classmates met face-to-face to celebrate the completion of their ... , ,Graduates gathered in Ophelia Parrish Performing Arts Center on the campus of Truman ...
... on tobacco and alcohol took place in June. The most popular ... 3.30 euros per packet. Are these taxes a form of dissuasion ... harm generated by those who smoke? A study by the Polytechnic ... the tobacco economy. The research, carried out by ...
... , , DALLAS, July 16 ... Baylor University Medical Center at Dallas (Baylor Dallas) in its America,s ... to achieve this distinction. , , ... Joel Allison, president and chief executive officer, Baylor Health Care System. ...
... , , , , ... a new technical assistance fact sheet on legal requirements relating to ... granting state licensure in occupations such as barbering, massage therapy and ... Persons with HIV and AIDS unfortunately still face obstacles ...
Cached Medicine News:Health News:Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid 2Health News:Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid 3Health News:Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid 4Health News:American Society for Clinical Pathology Joins the National Healthcare Career Network 2Health News:American Society for Clinical Pathology Joins the National Healthcare Career Network 3Health News:School of Health Management Honors 162 Graduating Students 2Health News:Is a society with smokers profitable? 2Health News:Is a society with smokers profitable? 3Health News:Baylor Dallas Recognized In U.S. News Media Group's 2009 - 2010 America's Best Hospitals 2Health News:Baylor Dallas Recognized In U.S. News Media Group's 2009 - 2010 America's Best Hospitals 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
Medicine Products: